Subcutaneous administration of epidermal growth factor: A true treatment option in case of postoperative liver failure?  by Glanemann, Matthias et al.
lable at ScienceDirect
International Journal of Surgery 7 (2009) 200–205Contents lists avaiInternational Journal of Surgery
journal homepage: www.thei js .comSubcutaneous administration of epidermal growth factor: A true treatment option
in case of postoperative liver failure?
Matthias Glanemann a,*,d, Baomin Shi a,b,d, Nadja El-Zidy a, Gereon Gaebelein a, Zienab Kronbach a,
Peter Neuhaus a, Andreas K. Nussler a,c
aDepartment of General-, Visceral-, and Transplantation Surgery, Charite´, Campus Virchow Klinikum, Universita¨tsmedizin Berlin, Berlin, Germany
bDepartment of Hepatobiliary Surgery, Shandong Provincial Hospital, Clinical College of Shandong University, Jinan, China
cDepartment of Traumatology, Technical University Munich, Munich, Germanya r t i c l e i n f o
Article history:
Received 27 January 2009
Received in revised form
11 March 2009
Accepted 17 March 2009






Epidermal growth factor (EGF)* Corresponding author. Department of General-, V
Platz 1, 13353 Berlin, Germany. Tel.: þ49 30 4505 52
E-mail address: matthias.glanemann@charite.de (M
d Authors contributed equally to this work.
1743-9191/$ – see front matter  2009 Surgical Asso
doi:10.1016/j.ijsu.2009.03.004a b s t r a c t
Adequate hepatocyte regeneration is mandatory for successful recovery after liver resection. The role of
epidermal growth factor (EGF), by subcutaneous injection as a simple route, has not been clearly
elucidated yet.
Wistar rats underwent 70 or 90% hepatectomy, respectively, and were treated with EGF at day 2 and 3
or served as non-EGF-treated controls. Postoperatively, proliferative parameters (weight of liver
remnants, number of mitotic and Ki-67 positive cells, expression of cyclin D1 protein) were evaluated.
After 90% hepatectomy, 5 day survival was recorded following EGF treatment using different dosages.
A signiﬁcant increase of hepatocellular proliferation was observed after 70% hepatectomy. However,
survival following 90% hepatectomy was not as positively affected, irrespective of EGF dosage, with most
animals dead before EGF application was completed.
Subcutaneous EGF injection can augment postoperative liver regeneration, however, it might be used
only as a prophylactic and not as a therapeutic drug in case of liver insufﬁciency.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Liver resection is still the major therapy for patients with
malignant tumors, since no adequate alternative modalities are
available. However, in case of large or multiple tumor lesions,
extended hepatectomy is usually regarded as undertaking a risk,
because of increased mortality due to postoperative liver failure in
face of low functional capacity of liver remnant. Much effort has
been placed on ﬁnding alternative effective methods such as
preoperative portal vein embolization or living-related liver
transplantation, but they are, however, still very limited.1–3
Acceleration of remnant liver regeneration might be the main-
stay, however, hepatocyte proliferation is a very complex process
involving many factors.4–6 Among these, the epidermal growth
factor (EGF), which has been studied for nearly two decades, is very
important.7–10 EGF is expressed in the adult liver under normal
physiological conditions, and is markedly upregulated during theisceral-, and Transplantation Surge
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ciates Ltd. Published by Elsevier Ltregenerative process after liver injury or partial hepatectomy. Thus,
it has been proven, that the administration of EGF accelerates the
proliferation of hepatocytes, regardless of what recombinant
protein or gene therapy strategy was used.11–15
In most experimental studies on liver regeneration, EGF was,
however, administered intraperitoneally or intravenously.15,16 In
view of an alternative approach, we focused in this study on the
subcutaneous administration, presenting an easier and safer way
especially in the clinical situation. Moreover, in most surgical
models EGF was evaluated with the intention to generally prevent
rather than to occasionally treat postoperative liver insufﬁciency in
case of need.14,16,17
We herein present a comparative analysis on partial (70%) and
subtotal (90%) liver resection in rats, which were treated with EGF in
order to evaluate whether application of this growth factor may: (i)
increase hepatocyte proliferation if subcutaneously administered;
and therebymay (ii) effectively treat postoperative liver insufﬁciency.ry, Charite´, Campus Virchow Klinikum, Universita¨tsmedizin Berlin, Augustenburger
d. All rights reserved.
M. Glanemann et al. / International Journal of Surgery 7 (2009) 200–205 2012. Methods
2.1. Animals and surgical procedure
The experimental design was reviewed and approved by the
local government (Senator fu¨r Gesundheit und Soziales, Berlin) and
carried out according to the European union regulations for animal
experiments, and were thus within the guidelines of the human
care for laboratory animals.
Male Wistar rats underwent liver surgery under isoﬂurane/
oxygen inhalative anesthesia. Rats were maintained with
commercial standard laboratory rat chow, a 12 h light/dark cycle,
constant temperature of 25 C and relative humidity of approxi-
mately 40%. They were acclimatized to our laboratory conditions
for 1 week prior to the experiments. Before and after intervention,
rats were allowed free access to food and tap water. Post-
operatively, 5% dextrose was offered ad libitum. An analgesia was
performed with tramadol s.c. and adapted to body weight after the
surgical procedure.
Liver resections were performed as previously described. Brieﬂy,
left andmedian liver lobes were removed after central ligaturewith
4-0 absorbable, synthetic, braided thread, in order to achieve
partial (70%) hepatectomy.18 In case of a subtotal (90%) hepatec-
tomy, the right upper and lower lobes were rendered necrotic by
additional ligation of the common right liver lobe pedicles using
braided silk thread. In the latter, both omental liver lobes and parts
of the liver tissue surrounding the intrahepatic portion of the
inferior vena cava remained in place, together representing
approximately 10% of the total liver mass.19
2.2. Experimental groups and protocol
2.2.1. Partial (70%) hepatectomy study
At day 2 and 3 after surgery, EGF (9 mg) was administered subcu-
taneously. Postoperative body weight was documented daily until
day 4 and 7 after surgery and compared to a non-EGF-treated control
group (n¼ 8 each group and each day). At the end of the observation
period animals were exsanguinated, and the remnant livers were
harvested, weighted and processed for (immuno-) histological anal-
ysis. Arterial blood samples were withdrawn for analysis of the
laboratory liver function tests. To obtain baseline levels of post-
operative hepatocellular proliferation, a further group of non-EGF-
treated animals was exsanguinated at day 1 after surgery.
2.2.2. Subtotal (90%) hepatectomy study
Five day survival was recorded after subtotal hepatectomy in
non-treated controls and in animals who received EGF subcuta-
neously at postoperative day 2 and 3 (dosage: 9, 25, or 50 mg;
n ¼ 8–10 each group).
2.3. Analysis of liver function and regeneration
2.3.1. Liver function tests
Serum AST, ALT, and GLDH plasma levels were measured using
commercially available reaction kits (Roche Diagnostics, Man-
nheim, Germany). The measurements were performed at the
Institute of Laboratory Medicine, Charite´, Campus Virchow Klini-
kum, Universita¨tsmedizin Berlin, Germany.
2.3.2. Mitotic index (histology)
Remnant liver tissue was ﬁxed in 4% phosphate buffered
formalin for 2–3 days, and then embedded in parafﬁn. From the
parafﬁn-embedded tissue blocks, 5 mm sections were cut and
stained with hematoxylin-eosin (HE). To evaluate hepatocyte
replication, mitotic ﬁgures were counted in 200-fold magniﬁcationand given as mitotic index (number of mitotic ﬁgures per 2000
hepatocytes).
2.3.3. Number of Ki-67 positive cells (immunohistochemistry)
The antibody MIB-5, which has been described to be reactive
with the rat equivalent Ki-67 protein and useful to monitor prolif-
eration in rat liver, was used for immunohistochemical analysis of
hepatocellular regeneration, using an indirect enzyme-linked anti-
body method. The proliferative capacity was quantitatively assessed
by counting the number of labeled hepatocytes per 2000 hepato-
cellular nuclei (200-fold magniﬁcation) and given as proliferative
index (number of Ki-67 positive cells per 2000 hepatocytes).
2.3.4. Expression of cyclin D1 protein (Western blot)
Expression of cyclin D1 protein, which is an indicator for DNA
replication and mitosis, was visualized using Western blot analysis.
Protein concentrations were determined using a commercially
available test based on the Lowry reaction (Sigma, Taufkirchen,
Germany). Proteins were separated on a 12.5% SDS polyacrylamide
gel, and then transferred onto nitrocellulose membranes. Non-
speciﬁc binding sites were blocked by a 5% non-fat milk solution
dissolved in PBS/Tween-20 at 4 C. Membranes were then washed
and incubated with speciﬁc antibody against cyclin D1 at room
temperature for 1 h. Membranes were then washed again (PBS/
Tween-20), and the immune complexes were visualized using
a chemiluminescence detection system (ECL; Amersham, Freiburg,
Germany). Equal loading of total protein was veriﬁed using
a commercially available antibody against b-actin (AC-15, Sigma,
Taufkirchen, Germany).2.4. Statistics
Results were expressed as means  SEM. After proving the
assumption of normality and equal variance, differences between
groups were assessed using ANOVA (overall differences), followed
by the appropriate post-hoc method. Differences in survival were
measured using the log rank test. Overall statistical signiﬁcancewas
set at p < 0.05. Statistics were performed using the software
package SPSS (SPSS Inc., USA).3. Results3.1.1. Partial (70%) hepatectomy study
In both groups, the resected liver volume was 6.3 and 6.5 g liver
tissue, representing about 2.4% of total body volume. No death
occurred during the postoperative observation period, resulting in
a 100% survival rate after partial (70%) hepatectomy (Table 1).
At day 4, postoperative administration of EGF statistically
signiﬁcantly increased the remnant liver mass by 31.7% higher
compared to the non-treated controls. At day 7, EGF-treated
animals still experienced an 11.6% higher increase of remnant liver
weight (Fig. 1).
Likewise, the number of mitotic cells was statistically signiﬁ-
cantly increased at day 4 in the EGF group compared to the control
group, reaching 12.6  4.9 versus 2.6  1.2 (p ¼ 0.011), respectively.
However, the increased proliferative activity was no longer
apparent, regardless of previous EGF administration, since
no meaningful number of mitotic ﬁgures were observed at day 7
(Table 2).
Similarly to the mitotic index, the number of Ki-67 positive cells
was also statistically signiﬁcantly increased by previous EGF
administration in comparison to controls, reaching 238.7  77
versus 40.1 13 at day 4 (p ¼ 0.001) and, at least, 19.4  16 versus
0 at day 7 (p ¼ 0.002), respectively (Table 2, Fig. 2).
Table 1
Animal characteristics and survival after partial (70%) and subtotal (90%) hepatectomy.
Parameters and study groups Partial (70%) hepatectomy Subtotal (90%) hepatectomy
Control EGF 9 mg Control EGF 9 mg EGF 25 mg EGF 50 mg
Body weight (g) 265  19 267  20 305  14 311  12 307  12 309  11
Liver weight – resected (g) 6.3  0.4 6.5  0.3 8.3  0.4 7.9  0.4 8.1  0.4 8  0.8
5 day survival (%) 100 100 10 (1/10) 25 (2/8) 25 (2/8) 35.7 (3/8)
Mean survival (days) n.a. n.a. 2.1  0.4 2.9  0.5 2.4  0.3 2.8  0.4
n.a. ¼ not analyzed, all animals survived.
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of hepatocytes, was also found to show an increased expression in
the EGF group at day 4 and 7 when compared to the control group
(Fig. 3).
The liver function test did not reveal any statistically signiﬁcant
differences in the plasma levels of AST or ALT. Only GLDH showed
a statistically signiﬁcantly lower serum concentration at day 4 in
the EGF group, reaching 118  27 versus 184  80 U/l (p ¼ 0.019)
(Table 3).
3.1.2. Subtotal (90%) hepatectomy study
Animals who underwent subtotal (90%) hepatectomy lost
between 7.9 and 8.3 g of liver tissue, which was about 2.6% of total
body volume (Table 1). In these, survival was markedly reduced
when compared to animals that underwent partial (70%) hepa-
tectomy, demonstrating the deleterious effects of postoperative
liver insufﬁciency. All but one animal in the control group died
within the ﬁrst days after surgery (mean survival of 2.1  0.4 days),
reaching a 5 day survival rate of 10%.
EGF treatment slightly increased the 5 day survival, however,
without reaching a statistically signiﬁcant difference. In the group
dependent on EGF, the survival increased up to 25% (9 or 25 mg) and
37.5% (50 mg) (Table 1). Nevertheless, the mean survival was as low
as in the control group (control: 2.1  0.4, EGF dosage 9 mg:
2.9  0.5, EGF dosage 25 mg: 2.4  0.5, EGF dosage 50 mg:
2.8  0.6 days), with most animals dying before the second growth
factor application at day 3 after surgery.
4. Discussion
Epidermal growth factor (EGF) is a polypeptide hormone
produced by glands of the gastrointestinal tract, namely the sali-
vary and Brunner’s glands. Noguchi et al. were the ﬁrst to report in
a study on the role of epidermal growth factor (EGF) in liver
regeneration. Treatment of sialoadenectomized mice with EGF
completely restored the postoperative pattern of DNA synthesisFig. 1. Total remnant liver weight at day 4 and 7 after partial (70%) hepatectomy. The
increase in the EGF group (open bars) was 31.7% higher at day 4 and 11.6% higher at day
7 compared to the increase in the corresponding control group (closed bars). Subcu-
taneous EGF administration was performed at day 2 and 3.after partial hepatectomy and increased total liver DNA content to
that of non-sialoadenectomized control mice.20 Meanwhile,
considerable in vitro and in vivo experiments have proved that EGF
may be one of the key factors in initiating liver regeneration after
partial hepatectomy or chemical injury.10,14–16,21,22 Moreover, it was
demonstrated that EGF is capable to reduce renal and gastroin-
testinal damage as well as death from chemically induced multi-
organ failure.23
The aim of the present studywas to highlight two questions. The
ﬁrst was to elucidate whether subcutaneous administration can
increase the hepatocellular proliferation rate as effectively as
intraperitoneally or intravenously administered (as evaluated in
prior studies), however, this is a safer and easier approach for drug
administration. The second question referred to the therapeutic
effects of EGF as a liver-support strategy. Since most experimental
studies evaluated its effect in a liver regeneration model (e.g. 30–
70% partial hepatectomy) with the intention to generally prevent
postoperative liver insufﬁciency,14,16,17,22 almost no sufﬁcient
information is availablewhether EGFmight also treat postoperative
liver failure, which might be evaluated in a model of acute liver
failure (e.g. subtotal (90%) hepatectomy).
With respect to the ﬁrst question, our results clearly showed
that subcutaneous EGF administration was very capable of
increasing hepatic proliferation. Indeed, following partial (70%)
hepatectomy, EGF treatment signiﬁcantly increased the remnant
liver mass by 31.7% at day 4, and even up to 11.6% at day 7. The
number of mitotic and Ki-67 positive cells and also the expression
of cyclin D1 protein were signiﬁcantly increased at day 4. EGF
dosage was according to the results of Rasmussen et al. who
showed that 6 nmol/kg BW (given IV over 24 h) effectively
increased hepatocellular proliferation.24 This amount is almost
equal to 9 mg/day in 250–300 g animals. In the same way, Noguchi
et al. also observed that subcutaneous administration of 5 mg EGF
led to a signiﬁcant increase of DNA synthesis.20 Although it is
difﬁcult to compare the different studies with regard to EGF
dosages and routes of application used, our results were very
consistent with the literature, showing strong proliferative effects
of EGF treatment in liver tissue,16,24,25 regardless of its route of
application.26,27
In the same line of evidence, several studies have clearly shown
that subcutaneous administration of EGF might effectively reach
other tissues as well. EGF subcutaneously administered augmented
healing of ulcerative gastrointestinal injury28–30 and enhanced
intestinal adaptation after massive small bowel resection.31 In
addition, Ribbons et al. reported that subcutaneous, but not intra-
luminal, EGF administration stimulated colonic growth.32
In our study EGF was administered at day 2 and 3 after surgery,
and the proliferative effects disappeared at day 7, indicating that
EGF experienced strong short-term stimulating effects. Longer
lasting effects may perhaps be achieved by a more frequent or
repeated application. On the other hand, one has to keep in mind
that EGF may also promote other tissues. Indeed, EGF led to
increasing growth in the prostate and small intestine, even in case
of subcutaneous administration,33–35 and a variety of tumors such
Table 2
Mitotic index and number of Ki-67 positive cells after partial (70%) hepatectomy (n/2000 hepatocytes).
Parameters and study groups Mitotic index Ki-67 positive cells
Control EGF p value Control EGF p value
Day 1 3  2.3 85.5  32
Day 4 2.6  1.2 12.6  4.9 0.011 40.1  13 238.7  77 0.001
Day 7 0 0.4  0.3 0.066 0 19.4  16 0.002
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express the EGF receptor.36
In consequence, we believe that side effects of the long-term
application of EGF may have to be seriously weighed concerning
the pros and cons. In our point of view there is only one indication
which might justify the yet unknown risks. Thus, acute post-
operative or acute (toxic) liver failure may justify EGF treatment in
terms of a liver-support strategy, since patients might otherwise
die because to date there are no other successful therapies
available.
Consequently, we evaluated the efﬁcacy of EGF treatment in
a model of acute postoperative liver failure. Therefore, animals
underwent subtotal (90%) hepatectomy, which is a life-threatening
situation due to seriously impaired liver function, in contrast to
partial (70%) hepatectomy, which is almost well tolerated with
a 100% survival.37 Within this study, EGF was subcutaneously
administered at day 2 and 3 after liver surgery in order to treat liverFig. 2. Parafﬁn-embedded liver sections with HE staining (A, B; magniﬁcation 400) a
hepatectomy. The mitotic index (A) as well as the number of Ki-67 positive cells (C) were
controls (B, D).insufﬁciency, and not pre- or perioperatively in order to prophy-
lactically prevent it.
Positively encouraged by the previous results of the regenera-
tion study after partial (70%) hepatectomy, we were very surprised
that EGF administration did not show the same promising results
after subtotal (90%) hepatectomy. Indeed, EGF administration did
not markedly improve the survival rate, irrespective of the
administered EGF dosage, with most animals dead due to liver
failure before the second EGF application was performed at post-
operative day 3.
The cause of the ineffectiveness possibly lies in the stimulating
mechanisms of DNA synthesis by EGF. Kimura et al. recently
reported that exogenous EGF and glycyrrhizin signiﬁcantly stimu-
lated both liver regeneration and recovery of function in vivo in
response to partial (70%) hepatectomy, and also proposed that both
of them possibly work via stimulation of EGF receptor.16 Indeed,
EGF can increase liver proliferation only in combination with EGFnd immunohistochemistry (C, D; magniﬁcation 400) at day 4 after partial (70%)
statistically signiﬁcantly increased by previous EGF administration in comparison to
Fig. 3. Western blot analysis of cyclin D1 protein expression (36 kDa) after partial (70%) hepatectomy.
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the proliferative effects of exogenous EGF would perhaps be
restricted due to the lack of available EGF receptors, which might
simply be a question of open quantity in need. In the same line of
evidence, Kiso et al. reported that hepatic EGF mRNA was upre-
gulated after partial (70%) hepatectomy reaching a maximum at 6 h
after surgery, whereas the number of EGF receptors decreased at
this time point.9
Moreover, we believe that ineffectiveness was not caused by too
small dosages of EGF. Rasmussen et al. and Ito et al. both showed
that EGF indeed worked in a dose-related manner with regard to
hepatocellular proliferation, but both groups clearly reported that
rather small dosages were stimulative while higher dosages were
ineffective.24,25
In addition, earlier administration of EGF (e.g. at day 0 after
surgery) would not fulﬁll the criteria of a therapy of need. Surgical
liver tissue removal itself may markedly release endogenous EGF
resources. As demonstrated by Kiso et al. EGF mRNA was upregu-
lated after partial (70%) hepatectomy in rats reaching its maximum
at 6 h, and EGF protein at 10 h after surgery.9 Thus, we believe that
exogenous EGF would not further improve the proliferative
capacity within the ﬁrst postoperative day, especially in view of
a dose-dependent relation.
It seems that remnant liver mass itself is more likely to be the
decisive obstacle. In this context, it is speculative whether portal
hyperperfusion or reduced liver mass mostly contributes to fatal
deterioration of liver function after extended resection. Indeed,
portal hyperperfusion has been considered responsible for organ
damage by hepatocyte ballooning, mitochondrial swelling, devel-
opment of irregular large gaps between sinusoidal lining cells, and
collapse of the space of Disse, as a result of shear-stress-induced
liver injury of sinusoidal lining cells.39 Nevertheless, EGF can
dramatically stimulate DNA synthesis and thereby augment the
remnant liver cell mass, however, it can not inﬂuence hepatic
microcirculation and not suddenly absorb the almost complete
breakdown of liver function. More than 40 years ago Bucher andTable 3
Serum concentrations of ALT, AST and GLDH after partial (70%) hepatectomy.
Parameters and study groups Control EGF
Day 4 AST (U/l) 84  37 114  49
ALT (U/l) 50  12 56  16
GLDH (U/l) 184  80 118  27*
Day 7 AST (U/l) 85  18 93  32
ALT (U/l) 42  9 43  8
GLDH (U/l) 14  4 19  7
*p ¼ 0.019.Swafﬁeld had already proposed that the extent of hepatocyte
replication in the regenerating liver of adult rats is proportional to
the amount of tissue resected for resections involving 40–70%
of the liver.40 However, the subtotal (90%) resection seems to
exceed the abrupt replicative capacity of the liver and, unfortu-
nately, EGF administration seems not to be useful to increase this
capacity fast enough because deterioration of liver function leads
rapidly to a breakdown of the whole organism.
In conclusion, EGF is a very strong liver regeneration stimulating
factor, regardless of its route of administration. Subcutaneous EGF
administration indeed increased the hepatocyte proliferation rate
by almost 30%, however, EGF should only be used as a prophylactic
drug to prevent postoperative liver insufﬁciency and not as a ther-
apeutic drug to treat postoperative liver failure.Conﬂict of interest
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